Gilead Sciences (GILD)
(Real Time Quote from BATS)
$62.47 USD
-1.61 (-2.51%)
Updated May 31, 2024 09:32 AM ET
5-Strong Sell of 5 5
C Value C Growth B Momentum B VGM
Brokerage Reports
Gilead Sciences, Inc. [GILD]
Reports for Purchase
Showing records 441 - 460 ( 523 total )
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
HCV Update: Vertex Reports Impressive Phase 1 Nuc Data; Seeking DAA(s) for Combination in Phase 2; Read-through for ACHN and IDIX
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Recent acquisitions & higher tax rate to keep earnings growth under pressure in CY12, but growth likely to pick up in CY13.
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Concern remains over lack of near term follow up products to offset pressure on topline growth.....
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Concern remains over lack of near term follow up products to offset pressure on topline growth.
Provider: FIRST GLOBAL
Analyst: THOMAS K